Morphea-like skin lesions reported in the phase 3 Long-Term Odanacatib Fracture Trial (LOFT) in postmenopausal women with osteoporosis

被引:2
|
作者
Saag, Kenneth G. [1 ]
de Villiers, Tobias J. [2 ,3 ]
Alexandersen, Peter [4 ]
Jacobe, Heidi [5 ]
Kovarik, Carrie [6 ]
Werth, Victoria P. [7 ]
Leung, Albert [8 ]
Desai-Merchant, Avani [8 ]
Mattaliano, Julie [8 ]
Gurner, Deborah [8 ]
机构
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Stellenbosch, Mediclin Panorama, Cape Town, South Africa
[3] Univ Stellenbosch, Dept Obstet & Gynaecol, Cape Town, South Africa
[4] Ctr Clin & Basic Res, Vejle, Denmark
[5] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX USA
[6] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
[7] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA
[8] Merck & Co Inc, Kenilworth, NJ USA
关键词
D O I
10.1016/j.jaad.2020.06.036
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
[No abstract available]
引用
收藏
页码:1113 / 1119
页数:7
相关论文
共 50 条
  • [1] Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
    Saag, Kenneth G.
    de Villiers, Tobie
    Alexandersen, Peter
    Jacobe, Heidi
    Kovarik, Carrie
    Werth, Victoria P.
    Leung, Albert
    Desai-Merchant, Avani
    Mattaliano, Julie
    Gurner, Deborah
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] EFFICACY OF ODANACATIB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: SUBGROUP ANALYSES OF DATA FROM THE PHASE 3 LONG-TERM ODANACATIB FRACTURE TRIAL (LOFT)
    Saag, K. G.
    Alexandersen, P.
    Benhamou, C. -L.
    Gilchrist, N.
    Halse, J.
    Lewiecki, E. M.
    Lippuner, K.
    McClung, M.
    Shiraki, M.
    DaSilva, C. A.
    Verbruggen, N.
    Scott, B. B.
    Lombardi, A.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S50 - S51
  • [3] Safety and Tolerability of Odanacatib Therapy in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT).
    Papapoulos, Socrates
    McClung, Michael
    Langdahl, Bente
    Saag, Kenneth
    Adami, Silvano
    Bone, Henry
    de Villiers, Tobias
    Kiel, Douglas
    Kung, Annie
    Kumar, Prasanna
    Lim, Sung-Kil
    Ling, Xu
    Lippuner, Kurt
    Mautalen, Carlos
    Nakamura, Toshitaka
    Reginster, Jean-Yves
    Reid, Ian
    Adolfo Rodriguez-Portales, Jose
    Roux, Christian
    Walliser, Jesus
    Watts, Nelson
    Ruben Zanchetta, Jose
    Zerbini, Christiano A. F.
    Fybak-Feiglin, Andrea
    Cohn, Dosinda
    da Silva, Carolyn A.
    De Tilleghem, Celine Le Bailly
    Santora, Arthur
    Scott, Boyd
    Verbruggen, Nadia
    Leung, Albert
    Lombardi, Antonio
    Gurner, Deborah
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S51 - S51
  • [4] ODANACATIB ANTIFRACTURE EFFICACY AND SAFETY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE PHASE III LONG-TERM ODANACATIB FRACTURE TRIAL (LOFT)
    McClung, M. R.
    Langdahl, B.
    Papapoulos, S.
    Saag, K. G.
    Adami, S.
    Bone, H. G.
    De Villiers, T.
    Kiel, D. P.
    Kung, A.
    Kumar, P. K. M.
    Lim, S. -K.
    Ling, X.
    Lippuner, K.
    Mautalen, C.
    Nakamura, T.
    Reginster, J. -Y.
    Reid, I. R.
    Rodriguez-Portales, A.
    Roux, C.
    Walliser, J.
    Watts, N. B.
    Zanchetta, J.
    Zerbini, C. A. F.
    Rybak-Feiglin, A.
    Cohn, D.
    DaSilva, C. A.
    Massaad, R.
    Santora, A. C.
    Scott, B. B.
    Kaufman, K. D.
    Verbruggen, N.
    Leung, A.
    Lombardi, A.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S35 - S36
  • [5] Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT).
    Recker, Robert
    Dempster, David
    de Villiers, Tobias
    Langdahl, Bente
    Miller, Paul
    Valter, Ivo
    Zerbini, Cristiano A. F.
    Cohn, Dosinda
    Doleckyj, Steven
    Duong, Le
    Scott, Boyd
    Verbruggen, Nadia
    Santora, Arthur
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S115 - S115
  • [6] Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-term Odanacatib Fracture Trial (LOFT)
    McClung, Michael R.
    Langdahl, Bente
    Papapoulos, Socrates
    Saag, Kenneth G.
    Bone, Henry
    Kiel, Douglas P.
    Lippuner, Kurt
    Nakamura, Toshitaka
    Reid, Ian
    Heyden, Norman
    DaSilva, Carolyn
    Scott, Boyd B.
    Massaad, Rachid
    Kaufman, Keith D.
    Stoch, S. Aubrey
    Santora, Arthur
    Gurner, Deborah
    Lombardi, Antonio
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2016, 23 (12): : 1369 - 1369
  • [7] Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis. Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT).
    McClung, Michael
    Langdahl, Bente
    Papapoulos, Socrates
    Saag, Kenneth
    Adami, Silvano
    Bone, Henry
    de Villiers, Tobias
    Kiel, Douglas
    Kung, Annie
    Kumar, Prasanna
    Lim, Sung-Kil
    Ling, Xu
    Lippuner, Kurt
    Mautalen, Carlos
    Nakamura, Toshitaka
    Reginster, Jean-Yves
    Reid, Ian
    Rodriguez Portales, Jose
    Roux, Christian
    Walliser, Jesus
    Watts, Nelson
    Ruben Zanchetta, Jose
    Zerbini, Cristiano
    Rybak-Feiglin, Andrea
    Cohn, Dosinda
    DaSilva, Carolyn
    Massaad, Rachid
    Santora, Arthur
    Scott, Boyd
    Verbruggen, Nadia
    Leung, Albert
    Lombardi, Antonio
    JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 : S51 - S51
  • [8] Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
    H. G. Bone
    D. W. Dempster
    J. A. Eisman
    S. L. Greenspan
    M. R. McClung
    T. Nakamura
    S. Papapoulos
    W. J. Shih
    A. Rybak-Feiglin
    A. C. Santora
    N. Verbruggen
    A. T. Leung
    A. Lombardi
    Osteoporosis International, 2015, 26 : 699 - 712
  • [9] Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial
    Saag, Kenneth G.
    Alexandersen, Peter
    Benhamou, Claude-Laurent
    Gilchrist, Nigel
    Halse, Johan
    Lewiecki, E. Michael
    Lippuner, Kurt
    McClung, Michael
    Shiraki, Masataka
    DaSilva, Carolyn A.
    Verbruggen, Nadia
    Scott, Boyd B.
    Lombardi, Antonio
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [10] Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
    Bone, H. G.
    Dempster, D. W.
    Eisman, J. A.
    Greenspan, S. L.
    Mcclung, M. R.
    Nakamura, T.
    Papapoulos, S.
    Shih, W. J.
    Rybak-Feiglin, A.
    Santora, A. C.
    Verbruggen, N.
    Leung, A. T.
    Lombardi, A.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (02) : 699 - 712